KEVIN NARDONE: Open Payments
NPI 1710469549 · WORCESTER, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,018 in 264 payments from 16 companies in 2025. Trend: 2023 $4,968 · 2024 $3,669 · 2025 $5,018
Food & beverage: $4,933Education: $85
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 53 | $1,187 |
| Otsuka America Pharmaceutical, Inc. | 42 | $628 |
| Alkermes, Inc. | 20 | $484 |
| ABBVIE INC. | 47 | $475 |
| E.R. Squibb & Sons, L.L.C. | 11 | $393 |
| Vanda Pharmaceuticals Inc. | 26 | $358 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $355 |
| Janssen Pharmaceuticals, Inc | 11 | $347 |
| Supernus Pharmaceuticals, Inc. | 11 | $285 |
| Lundbeck LLC | 12 | $215 |
Products named: AUSTEDO XR, REXULTI, VRAYLAR, UZEDY, COBENFY, CAPLYTA, FANAPT, Qelbree.
Industry payments across MA — which companies pay providers there.
